Slide 1: Integer Holdings Corporation (ITGR) Fourth Quarter 2025 Earnings Conference Call
Integer Holdings Corporation (ITGR) Fourth Quarter 2025 Earnings Conference Call February 19, 2026
Slide 2: Presenters and Agenda
Presenters and Agenda Today’s agenda: Payman Khales President, Chief Executive Officer • Opening Remarks • Strategy Update Diron Smith Executive Vice President, • Financial Results Chief Financial Officer • Financial Outlook • Wrap-up Kristen Stewart, CFA Director, Investor Relations • Q&A ITGR: 4Q2
Slide 3: Presentation of Financial Information & Forward-Looking Statements
Presentation of Financial Information & Forward-Looking Statements Important Information This presentation contains summarized information concerning Integer Holdings Corporation (the “Company”) and its business, operations, financial performance and trends. The historical financial and operating da
Slide 4: Opening Remarks
Opening Remarks O Integer’
Slide 5: Summary
Summary 4Q25 sales at the high end of outlook; delivered strong adjusted EPS growth in 2025 Delivered 2025 sales and • Sales increased 5% in 4Q25 and 8% for full year 2025 adj. EPS at high end of • Adjusted operating income increased 10% in 4Q25 and 13% for full year 2025 October outlook • Adjusted
Slide 6: Strategy Update
Strategy Update O Integer’
Slide 7: Integer at a Glance
Integer at a Glance A Leading Medical Device Contract Development & Manufacturing Organization (CDMO) Vision Improving patients’ lives around the globe, one device at a time Mission 10 ~$1.85B ~11,000 23 Advance the goals of our medical device customers through industry-leading engineering and manuf
Slide 8: Broad and Deep Portfolio of Capabilities and Product Offerings
Broad and Deep Portfolio of Capabilities and Product Offerings IPGs Batteries Catheters Machined Components Introducers Guidewires Speciality Delivery Coatings Systems Ablation Leads Textiles Extrusion Catheters & Coverings & Filmcast ITGR: 4Q25 Earnings Conference Call Not comprehensive; examples o
Slide 9: Investment Highlights
Investment Highlights High-performance culture focused on Well-positioned in attractive end markets customer-centricity, innovation, and with a focus on high-growth submarkets operational excellence Differentiated by deep technical expertise, Disciplined capital management focused breadth of capabil
Slide 10: Growth Teams Drive Product Line Strategies in High-Growth Markets
Growth Teams Drive Product Line Strategies in High-Growth Markets Markets Growth(1) Electrophysiology Mid-teens Dedicated, cross-functional teams responsible Structural Heart LDD for product line strategy and accountable for growth C&V Neurovascular HSD Deep understanding of target markets, custom
Slide 11: Expanding Capabilities in High-Growth Markets
Expanding Capabilities in High-Growth Markets Capability Investments Recent M&A Transactions Rapid prototyping, advanced automation, laser processing, extrusion, complex assemblies, implantable batteries, complex and micro machining, miniaturization, coatings, and catheter process platforming Guidin
Slide 12: Differentiated in the Eyes of our Customers
Differentiated in the Eyes of our Customers Technical Expertise Capability Breadth Innovative Technologies Scalable Manufacturing • Unparalleled subject matter • Comprehensive portfolio of • Extensive set of proprietary • Robust manufacturing and quality expertise across many technical engineered co
Slide 13: Robust and Diverse Pipeline Focused on Higher Growth Markets
Robust and Diverse Pipeline Focused on Higher Growth Markets Product development sales Strategy delivering mix shift to increased over 4x since 2017 higher growth markets ~50% ~20% ~20% ~20% Mature Higher ~50% ~80% ~80% ~80% Growth 2017 2021 2024 2025 2017 2021 2024 2025 Development Sales Developmen
Slide 14: Robust and Diverse Pipeline with Top OEMs and Emerging Innovators
Robust and Diverse Pipeline with Top OEMs and Emerging Innovators Markets Growth(1) Electrophysiology Peripheral Vascular • Diagnostic/mapping • AAA stenting Electrophysiology Mid-teens • Pulsed field ablation • Embolization • Renal denervation • Peripheral artery interventions • Transeptal access •
Slide 15: Strong Pipeline of Emerging Customers with PMA Products
Strong Pipeline of Emerging Customers with PMA Products ($ in millions) Product development through launch process Product introduction & launched customer sales # of customers currently in each phase (as of year end 2025) 15% - 20% 19 CAGR ~$125 10 6 5 ~$50 ~$20 ~$10 Development Clinical Regulatory
Slide 16: High-Performance Culture
High-Performance Culture Operational Focus Areas Values & Essentials CUSTOMER Customer Experience SUCCESS Impactful Innovation OPERATIONAL Integer Operating System EXCELLENCE Integer Production System LEADERSHIP Leadership Capability IMPACT Engaged Associates ITGR: 4Q25 Earnings Conference Call CONF
Slide 17: Disciplined Capital Management to Drive Sustainable Value Creation
Disciplined Capital Management to Drive Sustainable Value Creation • Technology, capabilities, automation, and capacity ORGANIC • Capex investments average 5.8% of sales over 2021-2025 period • Expect to continue investing to support growth outlook • Expand capabilities and exposure to high-growth m
Slide 18: Proven Track Record of Financial Performance
Proven Track Record of Financial Performance ($ in millions, except per share data) Sales Adj. Operating Income Adj. EPS Leverage CAGR (3 yr) 12% 21% 20% Within 2.5x - 3.5x target Organic 10% 368bps AOI margin expansion Organic sales change, adjusted operating income (AOI), AOI margin, adjusted EPS,
Slide 19: Strategic Financial Objectives Aligned to Create Long-Term Value
Strategic Financial Objectives Aligned to Create Long-Term Value Above-Market Organic Expand Disciplined Capital Sales Growth Profit Margins Management AOI Growth 2x Sales 2.5x - 3.5x 200bps Above Market Growth Rate Leverage Operational Excellence Prioritizing Organic Growth Customer-Centric and Dri
Slide 20: Financial Results
Financial Results O Integer’
Slide 21: 4Q25 Financial Results
4Q25 Financial Results ($ in millions, except per share amounts) Sales Adj. EBITDA Adj. Operating Income Adj. Net Income Adj. EPS Change 5% 11% 10% 22% 23% Organic 2% $472 $106 $449 $95 $83 $76 $62 $1.76 $51 $1.43 4Q24 4Q25 4Q24 4Q25 4Q24 4Q25 4Q24 4Q25 4Q24 4Q25 Organic sales change, adjusted EBITD
Slide 22: 2025 Financial Results
2025 Financial Results ($ in millions, except per share amounts) Sales Adj. EBITDA Adj. Operating Income Adj. Net Income Adj. EPS Change 8% 12% 13% 23% 21% Organic 6% $1,854 $402 $361 $1,717 $321 $285 $226 $6.40 $184 $5.30 2024 2025 2024 2025 2024 2025 2024 2025 2024 2025 Organic sales change, adjus
Slide 23: Cardio & Vascular
(1) % of Sales Cardio & Vascular ($ in millions) 60% Offering a full-range of products and services for catheter-based interventional vascular devices and a suite of supply chain solutions to support the development and manufacturing of complex components, sub-assemblies, and finished devices Quarte
Slide 24: Cardiac Rhythm Management & Neuromodulation (CRM&N)
(1) % of Sales Cardiac Rhythm Management & Neuromodulation (CRM&N) ($ in millions) 36%59% Providing technology solutions for the active implantable medical device industry by partnering with customers to bring high-quality products to established and emerging markets – from initial concept through h
Slide 25: 2025 Adjusted Net Income and EPS
2025 Adjusted Net Income and EPS ($ in millions, except per share amounts) Adj. Net Income Adjusted net income, adjusted EPS, adjusted interest expense, adjusted effective tax rate, and adjusted weighted average shares are non-GAAP financial measures; refer to “Non- ITGR: 4Q25 Earnings Conference Ca
Slide 26: Cash Flow and Leverage Trends
Cash Flow and Leverage Trends ($ in millions) Cash Flow From Ops Free Cash Flow Net Total Debt CAPEX Leverage $27 $19 $25 $19 $19 3.3x 3.2x 3.0x 3.0x 2.6x $1,230 $1,204 $1,158 $1,190 $63 $66 $55 $954 $44 $44 $46 $31 $28 $25 $6 4Q24 1Q25 2Q25 3Q25 4Q25 4Q24 1Q25 2Q25 3Q25 4Q25 4Q24 1Q25 2Q25 3Q25 4Q2
Slide 27: Financial Outlook
Financial Outlook O Integer’
Slide 28: 2026 Financial Outlook
2026 Financial Outlook ($ in millions, except per share amounts) Sales Adj. EBITDA Adj. Operating Income Adj. Net Income Adj. EPS Change (1)% - 1% (3)% - 3% (5)% - 1% (4)% - 3% (2)% - 6% Organic 0% - 3% $1,854 $1,826 - $1,876 $402 $391 - $415 $321 $304 - $324 $226 $216 - $232 $6.40 $6.29 - $6.78 202
Slide 29: 2026 Financial Outlook
2026 Financial Outlook ($ in millions) 2026 Sales Outlook • Reported sales down 1% to up 1% 4% - 6% • Organic sales flat to up 3% (1)% - 1% 2026 Product Line Sales Outlook $1,854 $1,826 - $1,876 • C&V sales flat to up low single digits due to a decline in two new (3)% - (4)% Electrophysiology produc
Slide 30: 2026 Cash Flow Outlook
2026 Cash Flow Outlook ($ in millions) Cash Flow From Ops Free Cash Flow Net Total Debt Leverage CAPEX Strategic Target: $105 $95 - $105 2.5x - 3.5x $91 $205 $200 - $220 $1,170 - $196 $1,190 $1,190 $954 3.0x 2.5x - 3.5x $100 - $120 $100 $105 2.6x 2024 2025 2026 2024 2025 2026 YE24 YE25 YE26 YE24 YE2
Slide 31: Wrap-Up
Wrap-Up O Integer’
Slide 32: Summary
Summary 4Q25 sales at the high end of outlook; delivered strong adjusted EPS growth in 2025 Delivered 2025 sales and • Sales increased 5% in 4Q25 and 8% for full year 2025 adj. EPS at high end of • Adjusted operating income increased 10% in 4Q25 and 13% for full year 2025 October outlook • Adjusted
Slide 33: Questions?
Questions?
Slide 34: Appendix
Appendix O Integer’
Slide 35: Acronym Reference Guide
Acronym Reference Guide ASR Accelerated Share Repurchase BCI Brain Computer Interface BPS Basis points C&V Cardio & Vascular Change Change on a year-over-year basis, unless noted COE Center of Excellence CRM Cardiac Rhythm Management CRM&N Cardiac Rhythm Management & Neuromodulation DD Double digit
Slide 36: 2026 Financial and Supplemental Financial Outlook
2026 Financial and Supplemental Financial Outlook ($ in millions, except per share amounts) 2026 Outlook(a) Supplemental Financial Outlook ITGR: 4Q25 Earnings Conference Call CONFIDENTIAL | February 19, 2026 | 36
Slide 37: Capitalization
Capitalization ($ in millions) 12/31/25 12/31/25 As Reported Rate Cash & Cash Equivalents $17 USD Denominated Revolver [Due 2028] - SOFR + 125bps EUR Denominated Revolver [Due 2028] - EURIBOR + 125bps TLA [Due 2028] $91 SOFR + 125bps Convertible Bonds [Due 2028] $116 2.125% fixed Convertible Bonds [
Slide 38: New Revenue Generation Cycle Times
New Revenue Generation Cycle Times Time to Manufacturing Existing Product Transfers Ramp Process Reg Begin Dev 0 – 6 Manufacturing 1 – 2+ 1 – 2 years months Ramp Years New 510k Products (Class II) Developed w/ Customers Clinical / Market Begin Product Development Regulatory Intro. Manufacturing 3 –
Slide 39: Historical Financial Results
Historical Financial Results ($ in millions, except per share amounts) Sales Adjusted EPS $1.79 $1.76 $476 $468 $472 $449 $437 $18 $1.55 $428 $431 $21 $21 $405 $408 $24 $18 $1.41 $1.43 $1.43 $28 $25 $29 $29 $1.30 $1.31 $172 $167 $169 $171 $160 $1.14 $168 $165 $153 $157 $287 $277 $284 $241 $255 $259
Slide 40: 4Q25 Adjusted Net Income and EPS
4Q25 Adjusted Net Income and EPS ($ in millions, except per share amounts) Adj. Net Income Adjusted net income, adjusted EPS, adjusted interest expense, adjusted effective tax rate, and adjusted weighted average shares are non-GAAP financial measures; refer to “Non- ITGR: 4Q25 Earnings Conference Ca
Slide 41: Product Line Review
Product Line Review O Integer’
Slide 42: Year-over-Year Sales Trend, Trailing Quarters
Year-over-Year Sales Trend, Trailing 4 Quarters Integer Cardio & Vascular % of Sales (1) 17% 18% 17% 14% 14% 60% 4Q24 1Q25 2Q25 3Q25 4Q25 10% 10% 10% 9% 8% CRM & Neuromodulation % of Sales (1) 38% 37% 8% 36% 6% 4Q24 1Q25 2Q25 3Q25 4Q25 5% 4% 1% 4Q24 1Q25 2Q25 3Q25 4Q25 ITGR: 4Q25 Earnings Conference
Slide 43: Other Markets
(1) % of Sales Other Markets ($ in millions) 4% Includes products from the divested AS&O product line, the Portable Medical market exit, and other products not included in Cardio & Vascular and Cardiac Rhythm Management & Neuromodulation Quarterly Sales Trailing 4 Quarter Sales 4Q25 sales decreased
Slide 44: Non-GAAP Financial Measures
Non-GAAP Financial Measures
Slide 45: Non-GAAP Financial Measures
Non-GAAP Financial Measures This presentation may contain the non-GAAP financial measures defined in the table below. A reconciliation of these non-GAAP financial measures to the most directly comparable GAAP financial measures can be found in the financial schedules accompanying the earnings releas
Slide 46: Non-GAAP Reconciliation
Non-GAAP Reconciliation 4Q25 Net Income and Diluted EPS Reconciliation – Detailed View ($ in thousands, except per share amounts) 2025 2024 GAAP Non-GAAP Non-GAAP As Reported, Restructuring and Continuing Amortization of restructuring- Acquisition and Other general Debt / Investment Operations intan
Slide 47: Non-GAAP Reconciliation
Non-GAAP Reconciliation YTD Net Income and Diluted EPS Reconciliation – Detailed View ($ in thousands, except per share amounts) 2025 2024 GAAP Non-GAAP Non-GAAP As Reported, Restructuring and Continuing Amortization of restructuring- Acquisition and Other general Debt / Investment Operations intang
Slide 48: Contact Information
Contact Information Kristen Stewart, CFA Director, Investor Relations kristen.stewart@integer.net (M) 551.337.3973 www.integer.net